ENABLEX 7.5 MG
DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG · DIN 02273217 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is ENABLEX?
ENABLEX 7.5 MG contains DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02273217, held by SEARCHLIGHT PHARMA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Apr-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ENABLEX used for?
ENABLEX (darifenacin) is indicated for the treatment of overactive bladder. Overactive bladder is used to describe a collection of urinary symptoms composed of urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of proven infection or other obvious pathology.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02273217 |
|---|---|
| Brand name | ENABLEX |
| Generic / active ingredient | DARIFENACIN (DARIFENACIN HYDROBROMIDE) : 7.5 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 7.5 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD10 DARIFENACIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Apr-2019 |
How is it stored and handled?
15 to 30 °C
How is it supplied?
HDPE bottle of 100 tablets. PVC/PVDC with aluminum foil blister pack of 7 tablets.
What can be used instead?
Other Canadian products sharing ATC code G04BD10 DARIFENACIN. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DARIFENACIN | 15 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452529 |
| APO-DARIFENACIN | 7.5 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452510 |
| ENABLEX | 15 MG | TABLET (EXTENDED-RELEASE) | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02273225 |
| JAMP DARIFENACIN | 15 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02491877 |
| JAMP DARIFENACIN | 7.5 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02491869 |
Who else supplies DARIFENACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DARIFENACIN appears in 22 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.